89Zr-曲妥珠单抗PET在标准检查无法确定HER2状态时支持乳腺癌临床决策
该可行性试验评估89Zr-曲妥珠单抗PET在标准检查无法确定乳腺癌患者HER2状态时能否支持诊断理解和临床决策,并评估循环肿瘤细胞HER2状态。20例患者中PET阳性12例、阴性7例、不明确1例,15/20例支持治疗决策,8例改变了治疗,18例改善了医生对疾病的理解;CTC HER2状态与PET结果或治疗决策无关。
要点
- 标准检查无法确定HER2状态时,89Zr-曲妥珠单抗PET在15/20例中支持治疗决策。
- PET改变了8例患者的治疗,并在10例中提高医生信心而不影响治疗。
- CTC HER2状态与89Zr-曲妥珠单抗PET结果或治疗决策无相关性。
核心结论
- 当标准检查无法确定HER2状态时,89Zr-曲妥珠单抗PET支持临床决策。
- CTC HER2状态的影响需进一步探索。
研究设计与样本
- 可行性试验,纳入标准检查后疾病HER2状态仍不明确的乳腺癌患者,共20例。
- 标准检查包括骨扫描、18F-FDG PET、CT,并在可行时进行活检。
- 将PET结果和现有肿瘤活检的中心病理复核报告给转诊医生。
- 转诊医生在89Zr-曲妥珠单抗PET前、后及≥3个月后完成诊断理解和治疗决策问卷。
- PET前评估CTC HER2状态,但事后分析且未报告给转诊医生。
主要发现
- 20例患者中,8例有两种原发癌(HER2阳性和HER2阴性乳腺癌,或乳腺癌和非乳腺癌),7例转移灶无法活检,4例有既往HER2阳性和阴性转移灶,1例原发乳腺癌HER2状态不明确。
- 89Zr-曲妥珠单抗PET阳性12例、阴性7例、不明确1例。
- 15/20例患者中,89Zr-曲妥珠单抗PET支持治疗决策。
- PET改变了8例患者的治疗,在10例中提高医生信心而不影响治疗,在18例中改善医生对疾病的理解。
- 10/20例患者检测到CTC,其中6/10例显示HER2表达;CTC HER2状态与89Zr-曲妥珠单抗PET结果或治疗决策无相关性。
临床怎么用
- 当标准检查(骨扫描、18F-FDG PET、CT及可行时活检)无法确定HER2状态时,89Zr-曲妥珠单抗PET可支持临床决策。
- CTC HER2状态的影响需进一步探索。
局限性
- CTC HER2状态的影响需进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Up-to-date information on human epidermal growth factor receptor 2 (HER2) status in breast cancer (BC) is important, as expression can vary during the course of the disease, necessitating anti-HER2 therapy adjustments. Repeat biopsies, however, are not always possible. In this feasibility trial we assessed whether 89Zr-trastuzumab PET could support diagnostic understanding and aid clinical decision making, when HER2 status could not be determined by standard work up. Additionally, HER2 status on circulating tumour cells (CTCs) was assessed. PATIENTS AND METHODS: 89Zr-trastuzumab PET was performed in patients if disease HER2 status remained unclear after standard work up (bone scan, 18F-FDG PET, CT and if feasible a biopsy). PET result and central pathologic revision of available tumour biopsies were reported to the referring physician. CTC HER2 status prior to PET was evaluated afterwards and therefore not reported. Diagnostic understanding and treatment decision questionnaires were completed by the referring physicians before, directly after and ≥ 3 months after 89Zr-trastuzumab PET. RESULTS: Twenty patients were enrolled: 8 with two primary cancers (HER2-positive and HER2-negative BC or BC and non-BC), 7 with metastases inaccessible for biopsy, 4 with prior HER2-positive and -negative metastases and 1 with primary BC with equivocal HER2 status. 89Zr-trastuzumab PET was positive in 12 patients, negative in 7 and equivocal in 1 patient. In 15/20 patients, 89Zr-trastuzumab PET supported treatment decision. The scan altered treatment of 8 patients, increased physicians' confidence without affecting treatment in 10, and improved physicians' disease understanding in 18 patients. In 10/20 patients CTCs were detected; 6/10 showed HER2 expression. CTC HER2 status was not correlated to 89Zr-trastuzumab PET result or treatment decision. CONCLUSION: 89Zr-trastuzumab PET supports clinical decision making when HER2 status cannot be determined by standard work up. The impact of CTC HER2 status needs to be further explored.
引用
- Bensch F, Brouwers AH, Lub-de Hooge MN, et al. 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur J Nucl Med Mol Imaging. 2018. PMID: 30058029. doi:10.1007/s00259-018-4099-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。